RET and neoplasm: Predictive biomarkers include gene fusions in ALK, ROS1, NTRK, and RET, sensitizing EGFR gene mutations, BRAF V600E point mutations, MET exon 14 skipping mutations and amplifications, PD-L1 expression, ERBB2 mutations, and tumor mutational burden.